HKUST Library Institutional Repository Banner

HKUST Institutional Repository >
Biology >
BIOL Conference Papers >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1783.1/997
Title: Genetically engineered antibodies targeting human liver cancer cells
Authors: Xie, Yong
Cheng, Samuel Chak-Sum
Huang, Yi-Wei
Chu, Siu-Hong
Chan, Kin Tak
Xie, Hong
Keywords: Genetic engineering
Monoclonal antibody
mAb-95
Single chain fragment (scFv) antibody molecule
scFv95
Hepatocellular carcinoma (HCC)
Complimentary determining region 3 (CDR3)
Issue Date: 2001
Citation: Proceedings advanced study institute on molecular genetic basis of cancer, Hong Kong, 6-12 Jan. 2001, HKUST, Hong Kong, 2001, p. 121-134
Abstract: This study involves the genetic engineering of a monoclonal antibody mAb-95 and the construction of a single chain fragment (scFv) antibody molecule (scFv95), both of which target human hepatocellular carcinoma (HCC). The mAb-95 was raised with crude membrane fragments of a human liver cancer cell line. Its specificity was confirmed by solid phase ELISA analysis, indirect immunostaining and immuno-gold labeling assays. To construct the scFv95, variable regions of Immunoglobulin (IgG) genes of mAb-95 were inserted into a bacterial expression vector, then expressed and characterized. The scFv95 was shown to have a binding ability to HCC cells. Mutagenesis experiments indicated that complimentary determining region 3 (CDR3) was important in binding to HCC. In particular, position 99 in CDR3 of the heavy chain was found to be crucial for scFv95's ability to bind to HCC. All results indicate that mAb-95 itself and the genetically engineered scFv95 could potentially be used as targeting agents for HCC immunotherapy or immuno-detection.
URI: http://hdl.handle.net/1783.1/997
Appears in Collections:BIOL Conference Papers

Files in This Item:

File Description SizeFormat
mgbc02.pdf1299KbAdobe PDFView/Open

All items in this Repository are protected by copyright, with all rights reserved.